Sigrun Hallmeyer

6.3k total citations
44 papers, 881 citations indexed

About

Sigrun Hallmeyer is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Sigrun Hallmeyer has authored 44 papers receiving a total of 881 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 15 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Sigrun Hallmeyer's work include CAR-T cell therapy research (24 papers), Virus-based gene therapy research (15 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Sigrun Hallmeyer is often cited by papers focused on CAR-T cell therapy research (24 papers), Virus-based gene therapy research (15 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Sigrun Hallmeyer collaborates with scholars based in United States, United Kingdom and Israel. Sigrun Hallmeyer's co-authors include Brendan D. Curti, Darren R. Shafren, Jon Richards, David Kushner, Jose Lutzky, Barbara L. Andersen, Debra L. Barton, Julia H. Rowland, Shari Damast and Shari Goldfarb and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sigrun Hallmeyer

41 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sigrun Hallmeyer United States	16	672	275	208	168	77	44	881
Stephanie Downs‐Canner United States	17	545 0.8×	278 1.0×	212 1.0×	231 1.4×	132 1.7×	57	1.1k
C. Lindemalm Sweden	17	428 0.6×	260 0.9×	125 0.6×	31 0.2×	87 1.1×	39	838
R. Rosenberg United States	7	434 0.6×	107 0.4×	88 0.4×	131 0.8×	47 0.6×	11	947
Patrick Elder United States	17	237 0.4×	166 0.6×	126 0.6×	35 0.2×	47 0.6×	71	768
Shawn F. Johnson United States	8	432 0.6×	304 1.1×	543 2.6×	59 0.4×	70 0.9×	13	1.1k
Fuat Oduncu Germany	23	643 1.0×	430 1.6×	576 2.8×	73 0.4×	62 0.8×	74	1.5k
Frank Alvaro Australia	15	173 0.3×	182 0.7×	102 0.5×	50 0.3×	46 0.6×	45	752
Swati Goel United States	13	227 0.3×	196 0.7×	335 1.6×	28 0.2×	51 0.7×	63	1.1k
Henry Goodfellow United Kingdom	8	156 0.2×	190 0.7×	257 1.2×	29 0.2×	54 0.7×	16	742
Sajan Jiv Singh Nagpal United States	13	517 0.8×	54 0.2×	267 1.3×	143 0.9×	84 1.1×	49	991

Countries citing papers authored by Sigrun Hallmeyer

Since Specialization

Citations

This map shows the geographic impact of Sigrun Hallmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sigrun Hallmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sigrun Hallmeyer more than expected).

Fields of papers citing papers by Sigrun Hallmeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sigrun Hallmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sigrun Hallmeyer. The network helps show where Sigrun Hallmeyer may publish in the future.

Co-authorship network of co-authors of Sigrun Hallmeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Sigrun Hallmeyer. A scholar is included among the top collaborators of Sigrun Hallmeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sigrun Hallmeyer. Sigrun Hallmeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Braun, Ilana M., Kari Bohlke, Donald I. Abrams, et al.. (2024). Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 42(13). 1575–1593. 23 indexed citations

Kirkwood, John M., Lisa A. Kottschade, Robert R. McWilliams, et al.. (2023). Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study. Immunotherapy. 16(1). 29–42. 3 indexed citations

Hallmeyer, Sigrun, et al.. (2023). Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing. Biology Methods and Protocols. 8(1). bpad002–bpad002. 1 indexed citations

Thompson, Michael A., et al.. (2022). Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies. SHILAP Revista de lepidopterología. 9(3). 149–157. 6 indexed citations

Milton, Denái R., William H. Sharfman, Bret Taback, et al.. (2021). An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. OncoImmunology. 10(1). 1984059–1984059. 5 indexed citations

Olson, Daniel J., Zeynep Eroglu, Bruce Brockstein, et al.. (2021). Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology. 39(24). 2647–2655. 136 indexed citations

Kirkwood, John M., Lisa A. Kottschade, Robert R. McWilliams, et al.. (2019). Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIzE).. Journal of Clinical Oncology. 37(15_suppl). e14144–e14144. 1 indexed citations

Olson, Daniel J., Jason J. Luke, Sigrun Hallmeyer, et al.. (2018). Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).. Journal of Clinical Oncology. 36(15_suppl). 9514–9514. 17 indexed citations

Hallmeyer, Sigrun, René González, David H. Lawson, et al.. (2017). Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Research. 27(6). 585–590. 20 indexed citations

10.

Carter, Jeanne, Christina Lacchetti, Barbara L. Andersen, et al.. (2017). Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. Journal of Clinical Oncology. 36(5). 492–511. 229 indexed citations

11.

Curti, Brendan D., Jon Richards, Sigrun Hallmeyer, et al.. (2017). Abstract CT114: The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment. Cancer Research. 77(13_Supplement). CT114–CT114. 23 indexed citations

12.

Chandran, Anjana, et al.. (2017). Safety and efficacy of concurrent administration of influenza vaccine in patients undergoing anti-PD-1 immunotherapy.. Journal of Clinical Oncology. 35(15_suppl). e14607–e14607. 9 indexed citations

13.

Hallmeyer, Sigrun, et al.. (2016). Sequencing of New and Old Therapies for Metastatic Melanoma. Current Treatment Options in Oncology. 17(10). 52–52. 6 indexed citations

14.

Buchbinder, Elizabeth I., Anasuya Gunturi, Janice P. Dutcher, et al.. (2016). A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. Journal for ImmunoTherapy of Cancer. 4(1). 52–52. 33 indexed citations

15.

Andtbacka, Robert H.I., Brendan D. Curti, Sigrun Hallmeyer, et al.. (2016). Abstract CT053: Intratumoral coxsackievirus A21 increases immune-cell infiltrates and upregulates immune-checkpoint molecules in the tumor microenvironment of advanced melanoma patients: phase II CALM extension study. Cancer Research. 76(14_Supplement). CT053–CT053. 1 indexed citations

16.

Mohiuddin, Majid, Harold S. Park, Sigrun Hallmeyer, & Jon Richards. (2015). High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma. Cureus. 7(12). e417–e417. 23 indexed citations

17.

Andtbacka, Robert Hans Ingemar, Brendan D. Curti, Howard L. Kaufman, et al.. (2015). Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.. Journal of Clinical Oncology. 33(15_suppl). 9030–9030. 54 indexed citations

18.

Andtbacka, Robert Hans Ingemar, Howard L. Kaufman, Lynn E. S̄pitler, et al.. (2014). Calm Study: Secondary Endpoints of a Phase Ii Study of a Novel Oncolytic Immunotherapeutic Agent, Coxsackievirus A21, Delivered Intratumorally in Patients with Advanced Malignant Melanoma. Annals of Oncology. 25. iv382–iv382. 2 indexed citations

19.

Radhakrishnan, Amruta, et al.. (2009). Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial. Journal of Chemotherapy. 21(4). 439–444. 6 indexed citations

20.

Hallmeyer, Sigrun, Nadim Mahmud, Linda R. Bressler, et al.. (2005). Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide. Cancer Immunology Immunotherapy. 55(9). 1033–1042. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact